TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07228364: A Phase I Randomised, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD1613 Following Multiple Ascending Dose Administration in Participants With Autosomal Dominant Po

Sponsor: AstraZeneca · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 40 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$270,912

Rescue Site Savings

+$180,608

Unlock Full NCT07228364 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07228364 Rescue Dossier →